Official White House Photo by Adam Schultz(WASHINGTON) President Joe Biden's new benchmark in the fight against COVID-19 ensuring 70% of American adults get at least one shot by July 4 seems to be a tacit acknowledgement of what scientists have been saying now for months: Eradicating the virus that causes COVID-19 might not be possible. But if enough Americans get some protection, it'll become manageable. That approach is being embraced by scientists and politicians alike as a considerably more pragmatic approach to dealing with COVID-19 than the idea of waiting on "herd immunity," especially considering that a fourth of Americans might never accept the vaccine. "We're going to have highs and lows of case numbers potentially for years, but those are going to be in the population that chooses not to vaccinate," said New Hampshire Gov. Chris Sununu in a phone interview Tuesday. Since the pandemic began, Americans have embraced the idea that the vi
Nikon Announces Judging Panel For The 47th Annual Nikon Small World Competition
Five expert judges will evaluate entries from around the world to select this year s winning microscopy images and movies.
News provided by
Share this article
Share this article
MELVILLE, N.Y., May 5, 2021 /PRNewswire/ Nikon Instruments Inc. today announced the judging panel for the 2021 annual Nikon Small World photomicrography and Small World in Motion video competitions.
Nikon Small World
Nsikan Akpan, Ph.D., Health and Science Editor at
New York Public Radio, Hank Green, Best-Selling Author, YouTube Creator, and Science Communicator, Robin Kazmier, Science Editor at
PBS NOVA, Alexa Mattheyses, Ph.D., Associate Professor of Cell, Developmental, and Integrative Biology at the University of Alabama, Birmingham, and Hesper Rego, Ph.D., Assistant Professor of Microbial Pathogenesis at the Yale School of Medicine will review and select the 2021 winning images and videos.
Credit: UAB
BIRMINGHAM, Ala. - A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program.
Formal Geriatric Assessment Should Be Routine medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Last year, researchers used a mouse model that included immune-reactive T cells from patients with Crohn s disease in a proof-of-principle demonstration that a flagellin-directed immunotherapy might provide similar benefits in. view more
Credit: UAB
BIRMINGHAM, Ala. - Last year, Charles O. Elson, M.D., demonstrated a potential preventive treatment for Crohn s disease, a form of inflammatory bowel disease. He used a mouse model that included immune-reactive T cells from patients with Crohn s disease in a flagellin peptide-specific immunotherapy. This study provided proof-of-principle that a flagellin-directed immunotherapy might provide similar benefits in patients.
Now University of Alabama at Birmingham researchers have moved a step closer to possible clinical testing of this treatment, say Elson and co-first authors Katie Alexander, Ph.D., and Qing Zhao, M.D., Ph.D. Their study, published in the journal